Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YPVKH
ADC Name
Pertuzumab zuvotolimod
Synonyms
Pertuzumab zuvotolimod; SBT6050; pertuzumab zuvotolimod
   Click to Show/Hide
Organization
Silverback Therapeutics, Inc.; ARS Pharmaceuticals, Inc.
Drug Status
Phase 1 (Terminated)
Indication
In total 1 Indication(s)
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Structure
Antibody Name
Pertuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (HER2)
  Antigen Info 
Payload Name
Analogue of motolimod
  Payload Info 
Therapeutic Target
Toll-like receptor 8 (TLR8)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random Cysteines
Combination Type
zuvotolimod
Puchem SID
472422606 , 461453647 , 476001025
ChEBI ID
CHEMBL5095143
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Objective Response Rate (ORR)  NCT04460456
Phase 1
A phase 1/1b, open-label, dose escalation and expansion study of SBT6050 alone and in combination with PD-1 inhibitors in subjects with advanced solid tumors expressing HER2.
Undisclosed  NCT05091528
Phase 1
An open-label, phase 1/2, dose-escalation and expansion study of SBT6050 combined with other HER2-directed therapies in subjects with pretreated unresectable locally advanced and/or metastatic HER2-expressing or HER2-amplified cancers.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
7.10%
Patients Enrolled
Patients have HER2-expressing or amplified solid tumors.
Administration Dosage
0.60 mg/kg administered Q2 weeks.
Related Clinical Trial
NCT Number NCT04460456  Clinical Status Phase 1
Clinical Description A phase 1/1b, open-label, dose escalation and expansion study of SBT6050 alone and in combination with PD-1 inhibitors in subjects with advanced solid tumors expressing HER2.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT05091528  Clinical Status Phase 1
Clinical Description An open-label, phase 1/2, dose-escalation and expansion study of SBT6050 combined with other HER2-directed therapies in subjects with pretreated unresectable locally advanced and/or metastatic HER2-expressing or HER2-amplified cancers.
References
Ref 1 A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results. 2020 Dec 7.
Ref 2 An Open-label, Phase 1/2, Dose-escalation and Expansion Study of SBT6050 Combined With Other HER2-directed Therapies in Subjects With Pretreated Unresectable Locally Advanced and/or Metastatic HER2-expressing or HER2-amplified Cancers, NCT05091528